Mundipharma expands its European footprint with Herceptin biosimilar

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/Shutter2U)
(Image: Getty/Shutter2U)

Related tags: Mundipharma, Prestige Biopharma, Herceptin, Biosimilars

Mundipharma partners with Prestige to commercialize and supply a biosimilar to Roche’s Herceptin, for patients with breast, gastric and gastroesophageal cancer.

The Cambridge, UK-based company announced a partnership with Prestige Biopharma, a Singaporian biosimilar developer, to exclusively distribute, market and sell Tuznue, a trastuzumab biosimilar treatment.

Mundipharma Europe will distribute the product in selected European countries including France, Spain, Norway, Sweden, Denmark, Finland, Portugal, Switzerland and Austria.

Tuznue is a biosimilar to Roche’s Herceptin, which is used to treat patients with human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer, HER2-overexpressing metastatic gastric cancer and gastroesophageal junction adenocarcinoma.

The European Medicines Agency (EMA) recently accepted a marketing authorisation application (MAA) for Tuznue, based on positive top-line results from global clinical trials.

This agreement sees the number of Mundipharma’s biosimilar partnerships for distribution in Europe rise to three, further building its footprint in the market.

Previously, Mundipharma partnered with Celltrion​ to commercialise Herzuma, another trastuzumab biosimilar, in seven European countries and has also launched Celltiron’s versions of J&J’s Remicade (infliximab), Remsima, and Roche’s Mabthera (rituximab), Truxima, within Europe.

“Using our collective expertise, Prestige in development, and us in commercialisation we can continue to reduce the financial burden for even more healthcare systems,”​ said Alberto Martinez, CEO of Mundipharma Europe.

Lisa Park, Prestige’s CEO commented that the partnership “will further increase the global availability of our trastuzumab biosimilar so that more patients can benefit from its quality and accessibility.”

“We envisage the partnership with Mundipharma to grow strong to encompass more programs in the future,”​ she added.

The product is expected to reach the market by the end of 2020.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Related suppliers

Follow us


View more